{"id":2663,"date":"2018-06-07T23:32:19","date_gmt":"2018-06-07T18:02:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2663"},"modified":"2021-07-24T12:57:00","modified_gmt":"2021-07-24T07:27:00","slug":"notizia-latest-pharma-news-6","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-6","title":{"rendered":"Axovant rely on gene therapy; CAR-T treatments; Pfizer\u2019s dacomitinib; Adaptimmune construct manifestation"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Axovant rely on new gene therapy, Rise in Shares\u00a0 <\/strong><\/p>\n<p style=\"text-align: justify;\">Roivant Neuro Company has licensed Oxford Biomedica\u2019s gene therapy OXB-102, now AXO-Lenti-PD, for Parkinson\u2019s disease (PD). Spark Therapeutics\u2019 Former CTO Fraser Wright, Ph.D has been hired as its new CTO.\u00a0Axovant expects to stimulate a phase 1\/2 dose escalation study in patients having PD. Axovant paid $30 million to gain Lenti-PD and ProSavin (a lentiviral vector-based gene therapy for PD).\u00a0Shares jumped around 100% on 6<sup>th<\/sup>\u00a0june, striking around $3.50.<\/p>\n<p style=\"text-align: justify;\">\n<p style=\"text-align: justify;\"><strong>CAR-T treatments can be secured by Amgen-developed RA drug<\/strong><\/p>\n<p style=\"text-align: justify;\">CAR-T cells\u00a0Gilead\u2019s Yescarta and Novartis\u2019s Kymriah,\u00a0used to treat blood cancers\u00a0can increase the risk of a side effect cytokine release syndrome (CRS). CRS include symptoms from rash and fever to severe neurological problems. Oncologists use drug Actemra to reverse CRS, but it doesn\u2019t block all the symptoms. Actemra, a Genentech drug works by obstructing interleukin-6 (IL-6), which is present in high levels in patients. Kineret developed by Amgen differs from Actemra as it is a small protein that can penetrate the brain, inhibiting neurological side effects of CRS.<\/p>\n<p style=\"text-align: justify;\"><strong>Pfizer\u2019s dacomitinib beat iressa in NSCLC overall survival face-off<\/strong><\/p>\n<p style=\"text-align: justify;\">A phase 3 trial has connected dacomitinib superior for the overall survival (OS) than Iressa in nonsmall cell lung cancer (NSCLC). Pfizer\u2019s EGFR tyrosine kinase inhibitor is more productive but the\u00a0 Tagrisso has\u00a0 an advantange in terms of safety and has capability to treat patients with CNS metastases. Pfizer debar people with the CNS metastases from the phase 3 trial because of doubt about the ability of dacomitinib to cross the blood-brain barrier.The factor might come into play when dacomitinib and Tagrisso start exchanging blows commercially.<\/p>\n<p style=\"text-align: justify;\"><strong>Adaptimmune construct manifestation for GlaxoSmithKline-partnered T-cell therapy.<\/strong><\/p>\n<p style=\"text-align: justify;\">T-cell therapies are used by Adaptimmune to demonstrate modernize clinical data. GlaxoSmithKline-partnered NY-ESO SPEAR T-cells to a 50% partial response rate in heavily pretreated cancer patients, 4 out of 8 MRCLS patients experienced partial responses (one unconfirmed) and 3 patients had stable disease. No antitumor effects were seen by Researchers when they administered 100 million MAGE-A10 cells to patients with non-small cell lung cancer and other solid tumors.\u00a0 The 1 billion cell dose was the therapeutic threshold.<\/p>\n<p style=\"text-align: justify;\"><strong>\u00a0<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Axovant rely on new gene therapy, Rise in Shares\u00a0 Roivant Neuro Company has licensed Oxford Biomedica\u2019s gene therapy OXB-102, now AXO-Lenti-PD, for Parkinson\u2019s disease (PD). Spark Therapeutics\u2019 Former CTO Fraser Wright, Ph.D has been hired as its new CTO.\u00a0Axovant expects to stimulate a phase 1\/2 dose escalation study in patients having PD. Axovant paid $30 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1536,831,2296,204,349,460,1196],"industry":[17225],"therapeutic_areas":[17235,17245,17228],"class_list":["post-2663","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-adaptimmune","tag-amgen","tag-axovant","tag-delveinsight","tag-latest-pharma-news","tag-pfizer","tag-pharma-research","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Axovant rely on gene therapy; CAR-T treatments; Pfizer\u2019s dacomitinib<\/title>\n<meta name=\"description\" content=\"Roivant Neuro Company has licensed Oxford Biomedica\u2019s gene therapy OXB-102, now AXO-Lenti-PD, for Parkinson\u2019s disease (PD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-6\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Axovant rely on gene therapy; CAR-T treatments; Pfizer\u2019s dacomitinib\" \/>\n<meta property=\"og:description\" content=\"Roivant Neuro Company has licensed Oxford Biomedica\u2019s gene therapy OXB-102, now AXO-Lenti-PD, for Parkinson\u2019s disease (PD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-6\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-06-07T18:02:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1112\" \/>\n\t<meta property=\"og:image:height\" content=\"660\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Axovant rely on gene therapy; CAR-T treatments; Pfizer\u2019s dacomitinib","description":"Roivant Neuro Company has licensed Oxford Biomedica\u2019s gene therapy OXB-102, now AXO-Lenti-PD, for Parkinson\u2019s disease (PD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-6","og_locale":"en_US","og_type":"article","og_title":"Axovant rely on gene therapy; CAR-T treatments; Pfizer\u2019s dacomitinib","og_description":"Roivant Neuro Company has licensed Oxford Biomedica\u2019s gene therapy OXB-102, now AXO-Lenti-PD, for Parkinson\u2019s disease (PD).","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-6","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-06-07T18:02:19+00:00","article_modified_time":"2021-07-24T07:27:00+00:00","og_image":[{"width":1112,"height":660,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-6","url":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-6","name":"Axovant rely on gene therapy; CAR-T treatments; Pfizer\u2019s dacomitinib","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-6#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-6#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","datePublished":"2018-06-07T18:02:19+00:00","dateModified":"2021-07-24T07:27:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Roivant Neuro Company has licensed Oxford Biomedica\u2019s gene therapy OXB-102, now AXO-Lenti-PD, for Parkinson\u2019s disease (PD).","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-6"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-6#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","width":1112,"height":660,"caption":"transthyretin amyloidosis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia-300x178.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Adaptimmune<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amgen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Axovant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma research<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Adaptimmune<\/span>","<span class=\"advgb-post-tax-term\">Amgen<\/span>","<span class=\"advgb-post-tax-term\">Axovant<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">pharma research<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jun 7, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jun 7, 2018 11:32 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"transthyretin amyloidosis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2663"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2663\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2465"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2663"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2663"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}